QURE · uniQure N.V.
$40.07
+3.41 (+9.30%)
At close · Jul 29
Market Cap
$2.53B
Shares
63.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$40.07
Open$38.00
Day$37.43–42.00
52W$8.73–71.50
Avg vol 30d2.6M
Short int10.4M · 16.4% float · 7.1d
Short vol47%
Last earningsJul 29, 2026
DataJan 2020–Jul 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 29, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+39%
above
Price vs 50-day avg
+11%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+50%
trailing
YTD return
+67%
this year
Relative strength
+44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $36 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
42 of 221 funds reported for Jun 30 · net +398.5K sh shares · +12 new
Insider flow
Distributing
Net -$2.4M over 90 days · 100% sells
Short interest
Falling
16.44% of float · ▼ -9.8% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
221 holders — mid 3-yr range
Squeeze score
83
high risk · 0–100
Fundamentals
Revenue growth
−48%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-178.4M
Balance sheet
$29.5M
net cash
Quant / Vol
risk profile
Volatility
284%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+39%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $36 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
42 of 221 funds reported for Jun 30 · net +398.5K sh shares · +12 new
Insider flow
Distributing
Net -$2.4M over 90 days · 100% sells
Short interest
Falling
16.44% of float · ▼ -9.8% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
221 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $9
Now $40 · 50%
52-wk high $72
vs 200-day avg +39%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QURE
this stock
uniQure N.V.
|
$2.53B | +67.4% | -47.8% | — | 16.4% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QURE | -0.8% | -13.0% | +50.4% | -13.0% | +67.5% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +1.6% | -10.7% | +44.1% | -10.7% | +60.5% |
Key facts
CIK
1590560
CUSIP
N90064101
13F (30d)
35 filings
35 filers
Visit website
Investor relations